Background: Modern immunosuppressive regimens, although associated with improved 1-year graft survival, are associated with adverse effects, including opportunistic infections, diabetes mellitus after transplantation, cardiovascular complications, and de novo malignancies. Objectives: To determine the short-term (12 months) cost-effectiveness of everolimus (EVR) versus mycophenolate sodium (MPS) in kidney transplant recipients receiving induction therapy, tacrolimus, prednisone, and no prophylaxis for cytomegalovirus infection. Methods: A Markov state transition model was designed. Data from a single-center prospective trial were used along with data from the center's medical bills database. The target population comprised adults with low immunological risk submitted to first ABO-compatible transplantation with kidneys recovered from living or deceased donors. The time horizon was 12 months. The interventions included tacrolimus and prednisone plus a single 3-mg/kg dose of rabbit antithymocyte globulin (ATG) and EVR or basiliximab (BAS) and EVR or BAS and MPS. The clinical outcomes considered for this analysis were cytomegalovirus infection/disease, acute rejection, graft dysfunction, surgical complications, graft loss, and life-years gained. Results: ATG/EVR was cost-saving compared with BAS/MPS on all evaluated outcomes; BAS/EVR outperformed BAS/MPS on most of the evaluated outcomes. Results were confirmed by sensitivity analysis. Conclusions: Compared with MPS, EVR is an alternative immunosuppressive agent that is able to provide resource-saving to the health care provider with effectiveness gains for the patient.
Introduction
Treatment for end-stage chronic kidney diseases, including dialysis or transplantation, is generally funded by public health insurance in developing countries [1, 2] . For kidney transplant recipients, immunosuppressive drugs constitute more than two-thirds of follow-up costs [3] . Modern immunosuppressive regimens, although associated with improved 1-year graft survival, are associated with adverse effects, including opportunistic infections, diabetes mellitus after transplantation, cardiovascular complications, and de novo malignancies [4] .
Cytomegalovirus (CMV) infection/disease is the most frequent opportunistic infection, being associated with increased morbidity, mortality, and costs after kidney transplantation [5, 6] . Because of the high efficacy for the prevention of acute rejection of modern immunosuppressive regimens, proper management of CMV infection/disease is mandatory. The two alternative strategies to manage CMV infection, universal prophylaxis and pre-emptive therapy, although relatively effective, are associated with increased costs and utilization of human resources [7, 8] .
Recent data have shown that the use of mammalian target of rapamycin inhibitors is associated with reduced incidence of CMV infection, with or without the use of pharmacological prophylaxis [9] . In this context, the objective of this study was to determine the cost-effectiveness of three immunosuppressive regimens in low to moderate immunological risk renal transplant recipients, receiving no CMV pharmacological prophylaxis under the perspective of the Brazilian public health care system. It is important to note that the study was conducted in the major reference center for kidney transplantation in Brazil (Hospital do Rim), which performed approximately 20% of the kidney transplants in the country. Therefore, the target population of this study is a clear representation of the patients who are usually found on daily practice around the country [10] . The results of this study can be of great relevance for decision makers because the choice of immunosuppressive regimen can be a major point of morbidity-related cost savings [11] .
Methods

Setting and Location
The Brazilian health care system (Sistema Único de Saude [SUS]) provides universal coverage to every Brazilian citizen. The country also has the second largest national transplant program, second only to the United States. About 8000 solid organ transplants are performed per year, 5556 of which are kidney transplants. More than 90% of these transplants are under the SUS system, making it the world's largest public program in this therapeutic area. The SUS coverage includes transplant procedures and follow-up care, including a lifelong supply of immunosuppressive medications [12] . Hospital do Rim, located in São Paulo, is a large kidney transplant center that treats patients from all regions of Brazil and performs about 900 kidney transplants per year. Similar to what is done in a national transplant program, more than 90% of these activities are performed through the SUS [10] .
Target Population
The modeled patient population comprised adults with low immunological risk submitted to first ABO-compatible transplantation with kidneys recovered from living or deceased donors [Supplemental material, Table1] . Clinical data from a prospective trial titled "Efficacy and safety of induction strategies combined with low tacrolimus exposure in patients submitted to kidney transplantation receiving everolimus or sodium mycophenolate" and registered on the Clinical Trials database as NCT01354301, involving 288 de novo kidney transplant recipients between July 11, 2011, and May 4, 2013, with a time horizon of 12 months [9] , were used as inputs to the economic model and to determine the cost-effectiveness of the comparators during the first year after renal transplantation.
Study Perspective
This study was developed from the perspective of the Brazilian public health care system (SUS), considering the resource use guidelines and costs from the transplant center. Although data were based on a single center, the guidelines and associated treatment costs were representative of the whole SUS, because guidelines and reimbursement costs are defined by federal policies. Besides that, the aforementioned transplant center performs approximately 20% of all renal transplants in Brazil. Thus, results can be generalized to the whole of SUS.
The perspective was chosen on the basis of the context of the Brazilian transplantation system, where most of the solid organ transplantations are performed under the SUS. This is the most relevant perspective to be evaluated.
Comparators
Three immunosuppressive regimens were evaluated. In the first group (rabbit antithymocyte globulin/everolimus [rATG/EVR], n ¼ 85), patients received r-ATG (single 3-mg/kg dose; Sanofi) as induction therapy, tacrolimus (TAC, 0.05 mg/kg twice a day; Libbs) adjusted to maintain whole blood trough concentrations below 5 ng/ml, EVR (1.5 mg twice a day; Novartis) adjusted to maintain whole blood trough concentrations between 4 and 8 ng/ ml, and prednisone. In the second group (basiliximab/everolimus [BAS/EVR], n ¼ 102), patients received BAS (20 mg on days 0 and 4; Novartis), TAC doses (0.1 mg/kg twice a day) adjusted to maintain whole blood trough concentrations between 3 and 8 ng/ml for the first 3 months and then reduced below 5 ng/ml, EVR doses (1.5 mg twice a day) adjusted to maintain whole blood trough concentrations between 4 and 8 ng/ml, and prednisone. In the third group (basiliximab/mycophenolate sodium [BAS/MPS], n ¼ 101), patients received BAS (20 mg on days 0 and 4), TAC doses (0.1 mg/ kg twice a day) adjusted to maintain whole blood trough concentrations between 6 and 8 ng/ml, MPS (720 mg twice a day; Novartis), and prednisone. Changes in the initial randomized immunosuppressive therapy were permitted either because of lack of efficacy or adverse events. All drugs were started within 24 hours of graft revascularization. None of these patients received any pharmacological prophylaxis for CMV infection. Pre-emptive strategy using pp65 antigenemia test was used for the first 6 months after transplantation.
When the core study was first designed, our hypothesis was that a single dose of ATG induction therapy or BAS in combination with low-dose TAC, EVR, and prednisone would result in comparable efficacy (biopsy-proven acute rejection) observed in patients receiving the standard regimen with TAC/MPS/prednisone but with a better safety profile. The rationale for the use of a single dose of ATG induction therapy was based on several previous studies that showed effective and safe results [13, 14] .
We anticipated that a single 3-mg/kg dose would provide protection against acute rejection during the first weeks after transplantation without increasing the risk of infections. The rationale for reduced exposure to TAC was based on the results of the Symphony trial [15] showing that targeting TAC concentrations between 3 and 7 ng/ml results in excellent efficacy and renal function. This regimen could also result in superior safety, namely, 1) lower incidence of viral infections, including CMV, herpes, and poliomavirus infection; 2) lower incidence of bacterial and fungal infections; 3) lower incidence of diarrhea; and 4) comparable renal function. This safety profile may be even better in those patients with EVR.
Time Horizon
Most of the possible complications arise in the first year after the graft transplantation. The relevant factors that impact long-term follow-up were evaluated in this analysis such as acute rejection, CMV infection/disease, surgical complications, and events related to treatment discontinuation. After one year of kidney transplant, the prevalence of these events is low and therefore less is the impact in graft and patient survival. For this reason, a more conservative time horizon (12 months) was chosen in order to observe this period which is the most relevance for long term follow up.
Discount Rate
No discount rate was applied because the time horizon was not more than 1 year.
Outcomes and Measurement of Effectiveness
The clinical outcomes considered for this analysis were CMV infection/disease, acute rejection, graft dysfunction, surgical complications, graft loss, and life-years gained. The economic outcomes contemplated in the analyses were direct medical costs, including medical resources used directly for patient treatment,
immunosuppression costs, treatment of adverse events, and follow-up of patients submitted to kidney transplantation.
The therapeutic effectiveness of comparators included in this analysis was based on the clinical trial that included 288 patients and evaluated clinical outcomes over 12 months after kidney transplantation [9] . It was chosen as the main source of clinical effectiveness because it was conducted in a major reference center for kidney transplantation in Brazil, depicting all the main characteristics of the target population and transplantation centers around the country. The annual incidence of adverse events, by treatment group, was evaluated from the adverse event registry form ( Table 1 ). The annual incidence of events, by treatment group, was adjusted to monthly transition probabilities used as parameters in the Markov model, through a Poisson model adjustment, according to the formula:
where t represents the time period (1 month) and λ the annual rate of events (Table 1) .
Resource Use and Treatment Costs
Health resources refer to costs associated with the immunosuppressive regimen, treatment of adverse events, and patient followup. Indirect and nonmedical direct costs, such as patient transportation, were not included in the evaluation because they were inadequate in terms of the adopted perspective. Immunosuppression costs were calculated according to the initial dosing regimens used by the patients in the clinical study. Although drug dose adjustments were made during the first year, it was found that this variation did not alter significantly the model results (Table 2) . Therefore, the cost of the initial drug dose was used all along the 12 months of simulation. Dose adjustment was analyzed in sensitivity analysis. Costs were obtained through the analysis of patient medical bills over the 12-month study follow-up period (July 2011 to May 2013). The total cost per patient in each event included all health resources available in the medical bill used by the patient during the treatment of that event. The duration of the event was surveyed through the adverse event clinical registration file. On the basis of the costs of the events from each patient included in the study, it was possible to calculate the average medical costs per event in each treatment group (Table 3) . Absorbing health states such as death, graft loss, and therapy discontinuation had no costs assigned to them. Death-related costs were already averaged on adverse events' treatment costs, and patients who discontinued treatment or lost the graft had all their costs counted until the time of the event. It is important to note that the treatment of adverse events was based on real data from the patients in each of the treatment groups. The difference seen between the mean values can be explained by the difference in the nature of the adverse events related to the treatment arm; that is, the higher CMV infection/disease treatment cost in the ATG/EVR arm can be explained by the fact that the first infection is usually more serious than the following ones and none of the patients in this group had recurrence of the infection.
All costs were converted from Brazilian real (R$) to US dollars using the average exchange rate along the duration of the clinical trial (US $1 ¼ R$1.9). The comparative results of alternative strategies were measured by incremental cost-effectiveness ratio (ICER), which was defined for the two alternative treatment strategies as the additional cost proposed by the new regimens divided by the additional gain in health (outcomes) according to the following formula:
Model Choice and Structure
The type of analysis selected was a cost-effectiveness analysis, once the model seeks to compare the direct medical costs and the † Complement probability of the sum of the following transition probabilities: no event, CMV infection/disease, graft dysfunction, surgical complication, and acute rejection.
V A L U E I N H E A L T H R E G I O N A L I S S U
clinical outcomes comparing two immunosuppressive regimens used in adults submitted to kidney transplantation. To estimate costs and outcomes of each treatment, a Markov model was designed to follow patients after kidney transplantation during 12 months [16] , because it is the most appropriate modeling option for time-recurring events. A modeling approach was chosen because at the time of the prospective trial design, no economic outcomes were defined and so costs could not be measured at the time. The model was used to generalize the modeled population and probabilistically estimate the time of an event occurrence. In this way, the model no more represents the exact population of the trial, but a broader population with the same baseline characteristics of the original one, showing a slightly different disease's natural history [17] . The chosen model structure is able to measure the occurrence of outcomes considered clinically and economically relevant in patients submitted to kidney transplantation, such as acute rejection, CMV infection, graft loss, and death. The model assumes that patients initiate immunosuppression immediately after the transplant (induction dose followed by maintenance dose). Patients enter into the model with good health conditions and are able to transit through other health states along the simulation cycles. Death can occur at any health stage and, in the occurrence of events, if the patient does not die, it is assumed that the patient returns to good health condition. Patients with loss of transplant and who discontinued treatment transit to their respective health stages and remain there until the end of the simulation (Fig. 1) .
Sensitivity Analysis
The quantification of uncertainty involved in the economic model and the identification of the variables mostly affecting such uncertainty are crucial to support decision making. A probabilistic sensitivity analysis was carried out to validate the results of this evaluation through the use of distributions, instead of the parameter values used in the mathematical model, to establish the impact of uncertainty of each parameter included in the study. The probabilistic sensibility analysis considers the variation of many parameters each time and was made through the attribution of a probability distribution appropriated to each of the analyzed parameters. All costs included in the analyses were varied by ±20% considering gamma distributions. Although arbitrary, this variation is sufficient to contain the average variation of all cost parameters adopted by the model. Beta distributions were used for transition probabilities, as well as efficacy and safety data. The beta distribution parameters used for the monthly transition probabilities were calculated on the basis of the values presented in Table 1 (rate and standard deviation), as the methodology described by Briggs et al. [11] . In the probabilistic analysis, 1000 simulations (second-order MonteCarlo simulation) [12] were estimated for each outcome. Results were evaluated and ranked as follows: first quadrant (incremental effectiveness 40 and incremental cost 40), second quadrant (incremental effectiveness o0 and incremental cost 40), third quadrant (incremental effectiveness o0 and incremental cost o0), and fourth quadrant (incremental effectiveness 40 and incremental cost o0).
Results
Cost-Effectiveness Analysis
The average total treatment costs per patient over a period of 12 months, according to the economic model, are presented in Table 4 . The results point toward the rATG/EVR immunosuppressive regimen as the one with more capacity to provide resourcesaving to the health care provider, saving approximately US $20,000 when compared with BAS/MPS in a 1-year time horizon. The BAS/EVR immunosuppressive regimen was associated with approximately US $8000 in savings, over the course of 1 year, when compared with the BAS/MPS immunosuppressive regimen. It is noted that the rATG/EVR immunosuppressive regimen 
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presented the lower cost associated with immunosuppression and treatment of adverse events as well. Nevertheless, the BAS/ EVR immunosuppressive regimen was associated with an annual cost that was higher by US $1300 when compared with the BAS/ MPS immunosuppressive regimen ( Table 4) . The effectiveness analysis revealed that rATG/EVR showed significant differences compared with BAS/MPS regarding the incidence of CMV infection/disease, graft dysfunction, and graft loss (Table 5 ). BAS/EVR was more effective than BAS/MPS in terms of CMV infection and graft loss.
The ICERs demonstrated that immunosuppression regimens with EVR provide resource-saving in relation to all evaluated outcomes (Fig. 2) . Although the rATG/EVR regimen was costsaving for all outcomes, the BAS/EVR regimen was cost-saving for CMV infection/disease and graft loss, demonstrating resourcesaving with an equivalent effectiveness in relation to other evaluated outcomes compared with the BAS/MPS regimen, respectively (Table 6 ).
Sensitivity Analysis
Probabilistic sensitivity analysis results for CMV infection/disease, graft dysfunction, and graft loss are shown in Figure 3 . The results refer to comparisons when there is a statistically significant difference between comparators (95% confidence interval ellipsoids do not cross the axis), in relation to cost and effectiveness. In the other comparisons, there was equivalence in terms of clinical outcomes between the immunosuppressive strategies and a significant difference between costs. After varying all costs involved in the analysis by ±20% by using gamma distributions and the transition probabilities, as well as efficacy and safety data by using beta distributions, the probabilistic sensitivity analysis confirmed the results observed in the base-case scenario.
Discussion
This trial was designed to investigate the incidence of CMV infection/disease in kidney transplant recipients receiving no pharmacological prophylaxis. The incidence of CMV infection/ disease may be higher than 60% in patients receiving no pharmacological prophylaxis, depending on the presence of several risk factors [17] . Our national health system does not reimburse either the use of pharmacological prophylaxis or the monitoring of CMV viral replication during pre-emptive strategy. Considering the current market value, pharmacological prophylaxis would add up to US $12,704 for 3 months or US $25,408 for 6 months of use, not including the direct and indirect costs associated with the treatment of antiviral drug-induced adverse events. Nevertheless, 
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monitoring of CMV viral replication is associated with an additional direct cost of US $1136, not including human resources and logistics, as observed in the standard-of-care mycophenolate arm. Clearly, an effective immunosuppressive regimen associated with a lower incidence of CMV infection/disease would be highly desirable.
The major difference in effectiveness in this study was derived from the incidence of CMV infection/disease, which was considerably lower in patients receiving EVR. The total number of CMV infection/disease treatments was 4.7, 17.6, and 57.4 in rATG/EVR, BAS/EVR, and BAS/MPS groups, respectively [9] . Because the incidence of CMV infection/disease among patients receiving EVR was quite low, even pre-emptive therapy was not necessary. In fact, out of 11 first episodes of CMV infection/ disease in the BAS/EVR group, 5 occurred after EVR discontinuation and 5 after treatment of an acute rejection episode. It is plausible that pre-emptive therapy could be used only in highrisk patients (Dþ/R−), after treatment of acute rejection or after EVR discontinuation, reducing even more the associated costs during the first year after transplantation.
The immunosuppressive regimen rATG/EVR is particularly attractive because it was associated not only with the lowest incidence of CMV infection/disease but also with low acute rejection. The total number of treated acute rejection episodes was 22.4, 34.3, and 28.7 in rATG/EVR, BAS/EVR, and BAS/MPS groups, respectively. The relationship between acute rejection and CMV infection is well known. CMV infection may trigger acute rejection, either by increasing the expression of human leucocyte antigens or by the need for reduction in the immunosuppression. Nonetheless, treatment of rejection increases the risk of CMV infection. In the trial, 25%, 45%, and 34% of first CMV infection/disease occurred after the treatment of an acute rejection episode in the rATG/EVR, BAS/EVR, and BAS/MPS groups, respectively [9] . It is difficult to predict the net effect of using higher TAC blood concentrations in the BAS/MPS group on the incidence of CMV infection. Although this strategy could be associated with a lower incidence of acute rejection and therefore a lower incidence of CMV infection after the treatment of acute rejection, the increase in overall immunosuppression could be associated with a higher incidence of CMV infection regardless of the treatment for acute rejection. The interplay of CMV infection and acute rejection may influence renal function, with all risk factors associated with inferior long-term transplant outcomes [18, 19] . Another important point is the discontinuation of the treatment that was lower in the rATG/EVR group compared with the other regimens (rATG/EVR [5 [9] . This is in contrast with previous data showing high dropout rates mainly because of adverse events observed in early conversion trials [20] . This observation may be a result of the use of lower but synergistic EVR and TAC exposures, leading to a lower incidence of clinically relevant events such as infection and acute rejection, preserving the tolerability of the regimen.
Previous pharmacoeconomic analysis suggested that a sirolimus-based calcineurin inhibitor (CNI) withdrawal regimen shows 
potential for long-term clinical benefits and is cost-saving compared with CNI-containing regimens [21] . Another study concluded that early transition to sirolimus provides long-term efficiency results compared with a TAC-based regimen [3] . Nevertheless, recent data showed increased incidence of de novo donor specific anti-human leucocyte antigen antibodies and antibodymediated acute rejection in patients undergoing similar strategy [22] , questioning the projected long-term benefits of this strategy. Therefore, an emerging new immunosuppressive strategy combining EVR and reduced exposure to TAC in de novo kidney transplant recipients has been investigated in a US randomized trial and an ongoing global trial (NCT01950819). Nevertheless, there are concerns regarding the de novo use of EVR, including surgical wound complications, incidence and duration of delayed graft function, graft dysfunction, and proteinuria [23, 24] . Compared with MPS, EVR treatment was not associated with lower effectiveness or higher costs regarding these particular outcomes in this 12-month analysis. Yet, long-term monitoring of EVR blood concentrations and drug class-related adverse events may mitigate the pharmacoeconomic benefits observed during the first year. This study is limited by its single-center nature, particular demographic characteristics of the transplant population, peculiar characteristics of the local public health care system, and restriction of the analysis to the first 12 months. Therefore, extrapolation to other populations assisted by different health care systems, as well as the prediction of long-term pharmacoeconomic benefits, may not be possible.
In brief, on the basis of real-time 12-month data, EVR is an alternative immunosuppressive agent that is able to provide resource-saving to the health provider with effectiveness gains for the patient as compared with standard-of-care therapy.
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